How Ph.D. was paid
$3.1M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Options | Incentive | Other | Total |
|---|---|---|---|---|---|
| Imran Alibhai, Ph.D.Chief Executive Officer and Director | $620,000 | $2,173,903 | $289,850 | $32,337 | $3,116,090 |
| Dan Conn, J.D., M.B.A.Chief Financial Officer | $450,000 | $536,451 | $153,000 | — | $1,139,451 |
| John Kauh, M.D.Chief Medical Officer | $500,000 | $454,315 | $170,000 | $32,337 | $1,156,652 |
| Christopher PosnerFormer (Cara) President and Chief Executive Officer | $203,933 | — | — | $2,366,327 | $2,570,260 |
| Ryan MaynardFormer (Cara) Chief Financial Officer | $134,013 | — | — | $997,899 | $1,131,912 |
| Scott TerrillionFormer (Cara) General Counsel, Secretary and Chief Compliance Officer | $129,935 | — | — | $982,503 | $1,112,438 |
What changed and why
- $3.1MCEO Imran Alibhai received total compensation of $3,116,090 in fiscal 2025 compared to $857,330 in the prior year.
- The increase in executive compensation was primarily driven by option awards granted in connection with the Merger and retention grants.
- 85%Corporate performance objectives for annual performance-based cash bonuses were determined to have been achieved at 85%.
- Certain former executives of Cara Therapeutics received termination and severance benefits following the completion of the Merger.
- The Board granted additional option awards in December 2025 as one-time retention compensation for employees.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.